10 October 2023
HALEON PLC
("Haleon" or "the Company")
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BMX86B70
Issuer Name
HALEON PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
GSK plc
City of registered office (if applicable)
BRENTFORD
Country of registered office (if applicable)
United Kingdom
| Name | City of registered office | Country of registered office |
| GSK GP 1 Limited | Edinburgh | Scotland |
| GSK LP Limited | London | England |
4. Details of the shareholder
| Name | City of registered office | Country of registered office |
| Vidacos Nominees Limited | London | England |
5. Date on which the threshold was crossed or reached
06-Oct-2023
6. Date on which Issuer notified
09-Oct-2023
7. Total positions of person(s) subject to the notification obligation
| % of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 7.420000 | 0.000000 | 7.420000 | 685320110 |
| Position of previous notification (if applicable) | 10.350000 | 0.000000 | 10.350000 | |
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
| Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |
| GB00BMX86B70 | 0 | 685320110 | 0.000000 | 7.420000 |
| Sub Total 8.A | 685320110 | 7.420000% | ||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
| Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
|
| | | | |
| Sub Total 8.B1 | | | | |
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
| Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |
|
| | | | | |
| Sub Total 8.B2 | | | | ||
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
| Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
| GSK plc (Chain 1) | | 2.850000 | | 2.850000% |
| GSK plc (Chain 1) | GlaxoSmithKline Holdings Limited (Chain 1) | 2.850000 | | 2.850000% |
| GSK plc (Chain 1) | GlaxoSmithKline Finance plc (Chain 1) | 2.850000 | | 2.850000% |
| GSK plc (Chain 1) | Glaxo Group Limited (Chain 1) | 2.850000 | | 2.850000% |
| GSK plc (Chain 2) | | 4.580000 | | 4.580000% |
| GSK plc (Chain 2) | GSK LP Limited (Chain 2) | 4.580000 | | 4.580000% |
| GSK plc (Chain 2) | GSK GP 1 Limited (Chain 2) | 4.580000 | | 4.580000% |
| GSK plc (Chain 2) | GSK (No. 1) Scottish Limited Partnership (Chain 2) | 4.580000 | | 4.580000% |
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
GSK plc is making this notification on behalf of itself and on behalf of GSK LP Limited and GSK GP 1 Limited.
This notification relates to the sale by GSK (No.1) Scottish Limited Partnership, GSK (No.2) Scottish Limited Partnership and GSK (No.3) Scottish Limited Partnership (entities that are indirectly wholly-owned by GSK plc) of (in the case of GSK (No.1) Scottish Limited Partnership) a portion of its interest and (in the case of GSK (No.2) Scottish Limited Partnership and GSK (No.3) Scottish Limited Partnership) all of their respective interests in Haleon plc.
GSK GP 1 Limited is the sole general partner of GSK (No.1) Scottish Limited Partnership and GSK (No.2) Scottish Limited Partnership. GSK LP Limited is the sole limited partner of GSK (No.1) Scottish Limited Partnership, GSK (No.2) Scottish Limited Partnership and GSK (No.3) Scottish Limited Partnership.
Glaxo Group Limited and GSK (No.1) Scottish Limited Partnership hold their shares in Haleon plc via a custodian, Vidacos Nominees Limited, which holds the legal title to those shares on their behalf pursuant to a custody arrangement.
12. Date of Completion
09-Oct-2023
13. Place Of Completion
London, England
Amanda Mellor, Company Secretary
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
